



Market Announcement

30 September 2022

Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt

Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 4 October 2022 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

ASX RELEASE

30 September 2022

By email: melissa.kostopoulos@asx.com.au

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Limited

Dear Melissa

Request for a trading halt

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

The Company has received biomarker and clinical data from an independent contract research organisation (CRO) relating to its phase II PARA_008 clinical trial. The Company is requesting a trading halt so it has time to analyse the data and prepare an ASX Announcement and webinar presentation on the data, to be released to the market on Tuesday 4 October 2022. Accordingly pursuant to ASX Listing Rule 17.1, the Company requests the trading halt in order to finalise its review and update to the market.

The Company requests that the trading halt remains in place until the earlier of the Company making an announcement in relation to the received PARA_008 data or commencement of trading on Tuesday 4 October 2022.

The Company is not aware of any reason why the trading halt should not be granted.

Authorised for release on behalf of the Board of Paradigm Biopharmaceuticals Limited

Yours faithfully,



Abby Macnish Niven

Company Secretary